DJ Neuren's Deal With FDA Reduces Uncertainty -- Market Talk
18:05 [Dow Jones] Neuren Pharmaceuticals's (NEU.AU) agreement with U.S. regulators on the
design of a Phase 3 trial of its trofinetide treatment for Rett Syndrome makes the stock
a less risky bet, says Bell Potter. The broker lifts its price target by 31% to
A$0.17/share, and expects Neuren's partnering talks will now accelerate. "Subject to a
partnering deal for trofinetide concluding in 1Q 2018, we expect that a Phase 3 trial for
Rett could start in 2H 2018," says Bell Potter, which retains a buy call on the stock.
([email protected]; @dwinningWSJ)
(END) Dow Jones Newswires
October 17, 2017 18:05 ET (22:05 GMT)
Copyright(c) 2017 Dow Jones & Company, Inc.
Wednesday 18 October 2017 09:05:00.000 AEST
Bell potter 17c target, page-3
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |